Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib alone and with pembrolizumab in first-line KRAS G12C-mutated advanced non-small cell lung cancer
MOH_2022-08-09_011970Phase 3Recruiting
- Sponsor
- Mirati Therapeutics
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of adagrasib and pembrolizumab in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Mirati Therapeutics. Primary endpoints: Phase 2 efficacy evaluation and Phase 3 efficacy comparison. Started Aug 2022; status: recruiting.
02
Drugs
adagrasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2022-08-09_011970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-09_011970.